GlassScriptPhysician profile
Thomas G Lewis
NPI 1043429640
$4,480.46
in general payments reported to CMS, 2019-2025
30 companies · $72.48 in 2025
The $72.48 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $277 · 2021: $707 · 2022: $460 · 2023: $765 · 2024: $1,067 · 2025: $72.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,888.31 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,615.46 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $488.56 | 2019-2024 | |
| Janssen Biotech, INC. | $472.52 | 2019-2024 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $349.06 | 2019-2024 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $263.33 | 2019-2024 | Siliq |
| Ucb, INC. | $177.84 | 2019-2024 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.86 | 2023-2024 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $144.31 | 2019-2024 | Dupixent, Libtayo |
| Incyte Corporation | $106.97 | 2021-2024 | Opzelura |
| Amgen INC. | $99.59 | 2019-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $91.25 | 2019-2024 | Odomzo, Blu-U |
| Pfizer INC. | $82.26 | 2019-2024 | |
| Biofrontera INC. | $61.30 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Genentech USA, INC. | $53.05 | 2019 | |
| Genzyme Corporation | $46.32 | 2019-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $38.54 | 2023 | Visiclear |
| Merck Sharp & Dohme LLC | $26.91 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.67 | 2025 | |
| Botanix Sb INC | $25.31 | 2025 | Sofdra |
| Mallinckrodt Hospital Products INC. | $22.66 | 2023 | Acthar |
| Krystal Biotech INC | $18.71 | 2024 | Vyjuvek |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.50 | 2024 | Xifaxan |
| Fresenius Kabi USA, LLC | $15.33 | 2023 | Idacio |
| Blueprint Medicines Corporation | $14.65 | 2023 | |
| Galderma Laboratories, L.P. | $13.57 | 2019 | |
| Dusa Pharmaceuticals, INC. | $12.99 | 2019 | |
| Mylan Institutional INC. | $12.96 | 2023 | Hulio |
| Leo Pharma INC. | $12.61 | 2021 | |
| Vyne Pharmaceuticals INC. | $12.49 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.